Safety Observation on hESC Derived MSC Like Cell for the Meniscus Injury

Tongji Hospital

Status and phase

Unknown

Phase 1

Conditions

Meniscus Injury

Treatments

Biological: hESC derived MSC like cell

Study type

Interventional

Funder types

Other

Identifiers

NCT03839238

Wuhan Tongji Hospital

Details and patient eligibility

About

human embryonic stem cell derived mesenchymal stem cells like cell for the meniscus injury, and observe the safety of the cells for meniscus injury

Full description

Three different dosage of human embryonic stem cell derived mesenchymal stem cells like for meniscus injury patients, and observe the safety of the cells for meniscus injury.

Enrollment

18 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Grade Ⅰ-Ⅱ meniscus injury of knee joint
The patients who still have the pain of knee joint and/or limitation of the function after accepted 3 months of nonoperative treatment

Exclusion criteria

Recent history of lower limb fractures or intra-articular drug injection
The patients who have meniscus injury of knee joint need the surgical repair
The patients who have the severe coagulation disorders, cardiopulmonary failure and so on
The women who are pregnant or nursing
There are electronic implants such as pacemakers in the body
The patients who are infected the HIV, the virus of hepatitis or syphilis
The patients who are alcoholism or drug user
The patients who have vestibular and balance disorders
The patients with severe cognitive impairment who cannot follow instructions to complete the treatment
The patients who don't sign the informed consent
The patients who have tumor
Immunodeficiency patients
The patients who have congenital or acquired knee malformation
Patients or researchers who are participating in other clinical trials believe that other reasons are not appropriate for clinical trials